WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals
World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

ISSN 2457-0400

Impact Factor  :  5.464

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • WJAHR New Impact Factor

    Its our Pleasure to Inform you that WJAHR Impact Factor has been increased from  4.897 to 5.464 due to high quality Publication at International Level

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • WJAHR: MAY ISSUE PUBLISHED

    MAY 2022 Issue has been successfully launched on 1 May 2022

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR 1 May Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

Abstract

GENEXPERT MTB/RIF DIAGNOSTIC AND TUBERCULOSIS TREATMENT INITIATION DELAYS IN NAMIBIA

Francis F. Chikuse*, Loveness N. Dzikiti, Auxilia Chideme-Munodawafa, Talkmore Maruta, Greanious A. Mavondo, Munyaradzi Mukesi, Mathew Maisiri, Patricia T. Gundidza, Han J. Amukugo, Larai A. Akai, Munyaradzi M. Soko

ABSTRACT

Background: Early diagnosis and treatment of drug resistant tuberculosis are crucial in the control of the disease and treatment success. In Namibia, there is a gap in empirical data on the diagnosis and treatment initiation delay time since the roll-out of the GeneXpert MTB/RIF (Xpert) assay in 2017. This study aimed to determine Xpert pre-diagnosis and turnaround time at Namibian Institute of Pathology (NIP) as well as rifampicin resistant tuberculosis (RR-TB) treatment initiation delay on patients admitted at Katutura Intermediate Hospital TB clinic. Methods: This was retrospective descriptive cross-sectional study which was conducted from 1 July 2018 to 31 March 2019. A total of seventy two participants comprising of twenty five RR-TB and forty seven non RR-TB patients were enrolled using consecutive sampling method. Laboratory information system (LIS) was utilized to determine Xpert median pre-analytical delay and turnaround time. Patients’ records and LIS were used to calculate median treatment initiation delay time post Xpert diagnosis. Data on continuous variables was summarized as median and interquartile range. Results: The median pre-diagnostic, diagnostic and treatment initiation delay time were 7.5 (IQR: 0-14), 1 (IQR: 0-3) and 10 (IQR: 1-32) days respectively for RR-TB. For drug susceptible TB, the median pre-diagnostic, diagnostic and treatment initiation delay time were 5 (IQR: 1-8), 1 (IQR: 0-3) and 3 (IQR: 0-12) days respectively. Overall, median health system delay time was 21 (IQR: 2-32) days for RR-TB patients and 12 (IQR: 1-12) days for non RR-TB patients. Conclusion: Treatment initiation to appropriate second line regimes was long for many patients and may be attributable to poor interpretation of discordant results and increased number of RR-TB patients for treatment since Xpert adoption. Unnecessary referrals due to shortages of pulmonologists, cumbersome baseline investigations and outdated guidelines and policies could be the determinants of health system delay time. Interventions targeted at addressing identified factors should be implemented. Further studies should explore the actual treatment gap among RR-TB patients and further risk factors for delayed treatment.

[Full Text Article]